Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by pierre013on Jun 01, 2017 2:30pm
341 Views
Post# 26312547

June 5th is not a final date for priority review

June 5th is not a final date for priority reviewLook at what Francois21 had just told us on the french bullboard :

Le fameux 5 juin n'est pas la date prvue d'approbation du plasminogne. 

Les gens spculent l'effet que lorsque une "priority review" est demand, la FDA rpond normalement en 60 jours. Comme PLI avait annonc la soumission finale du BLA le 5 avril, des gens anticipent une rponse de la FDA pour le 5 juin. 

Si la FDA accepte la revue prioritaire, normalement l'approbation peut tre donn dans un dlai de 6 mois, plutt que dans le dlai moyen de 10 mois.

Si on se fie aux lignes directrices de la FDA, les chances sont bonnes:

A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.

Significant improvement may be demonstrated by the following examples:
•evidence of increased effectiveness in treatment, prevention, or diagnosis of condition;
•elimination or substantial reduction of a treatment-limiting drug reaction;
•documented enhancement of patient compliance that is expected to lead to an improvement in serious outcomes; or
•evidence of safety and effectiveness in a new subpopulation

From my understanding, there is no limit of time to answer for a priority review. So it's possible that the FDA takes another month before giving the approval for a priority review. So we have to wait and see..

GLTA

Bullboard Posts